Research peogramme: Nucleotide modulating therapeutic - Redona Therapeutics
Latest Information Update: 19 Dec 2025
At a glance
- Originator Redona Therapeutics
- Class
- Mechanism of Action Nucleotide modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 05 Dec 2025 Early research in Unspecified in USA (unspecified route), prior to December 2025 (Redona Therapeutics pipeline, December 2025)